Avitar Announces Stock Report Issued by Standard & Poor's

August 27, 2001

CANTON, Mass., Aug. 27 /PRNewswire/ -- Avitar, Inc. (Amex: - news) today announced that a Stock Report on the company has been issued by Standard & Poor's (S&P) under its Stock Reports Coverage Program.

The equity research coverage by the assigned S&P analyst, which will be continually updated, was made available today to millions of investors. They include sell-side and buy side investment houses, over 100,000 retail brokers, account holders at numerous online brokerages, the Multex Investor network, 170,000 members of the American Association of Individual Investors (AAII), and 750,000 members of the National Association of Investors Corporation (NAIC), as well as numerous Canadian outlets.

``The S&P report is a continuation of efforts to broaden exposure of our company to the investing public, and we are pleased that a universally respected organization such as Standard and Poor's has issued a Stock Report on Avitar,'' said Peter P. Phildius, Avitar's Chairman and Chief Executive Officer. ``This will allow the investment community to access timely information on Avitar from one of the broadest distribution networks in the world.''

ABOUT AVITAR

Avitar, Inc. (Amex: - news) headquartered in Canton, Massachusetts, is a diagnostics company that develops, manufactures and markets innovative and proprietary medical devices in two major areas: the oral fluid drugs-of-abuse market and the disease & clinical testing market. Oral fluid diagnostics includes both the drugs-of-abuse testing market estimated to be worth $1.5 billion encompassing the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, and HAIRscreen(TM), a laboratory-based hair test for detecting long-term drug abuse. In the $20 billion disease & clinical testing market, Avitar is currently developing products that will address the conditions of Lyme disease, influenza and diabetes, as well as pregnancy. For more information, see Avitar's website at avitarinc.com.

This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission.